New roles and evidence for weight-loss procedures during the rise of glucagon-like peptide-1 medicines

National trends indicate increased use of GLP-1 receptor agonists in obesity management.

• Endobariatrics are minimally invasive therapies that provide durable weight loss with low complication rates.
• Patient comorbidities and socioeconomic factors are important in selecting treatment options.
• Emerging evidence suggests that combining GLP-1 receptor agonists with endobariatric therapies may lead to enhanced weight loss effects.
• A personalized approach to treatment that includes both pharmacotherapy and mechanism-based interventions may improve long-term weight loss outcomes.
• A multidisciplinary approach is critical for effective comprehensive care in obesity management.

Simplified